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ABSTRACT
It has recently been suggested that the chemokine receptor (CCR5) is required for 
bone marrow (BM) derived endothelial progenitor cell (EPC) mediated angiogenesis. 
Here we show that suppression of either cancer cell produced CCL5, or host CCR5 
leads to distinctive vascular and tumor growth defects in breast cancer. Surprisingly, 
CCR5 restoration in the BM alone was not sufficient to rescue the wild type phenotype, 
suggesting that impaired tumor growth associated with inhibiting CCL5/CCR5 is not 
due to defects in EPC biology. Instead, to promote angiogenesis cancer cell CCL5 may 
signal directly to endothelium in the tumor-stroma. In support of this hypothesis, we 
have also shown: (i) that endothelial cell CCR5 levels increases in response to tumor-
conditioned media; (ii) that the amount of CCR5+ tumor vasculature correlates with 
invasive grade; and (iii) that inhibition of CCL5/CCR5 signaling impairs endothelial cell 
migration, associated with a decrease in activation of mTOR/AKT pathway members. 
Finally, we show that treatment with CCR5 antagonist results in less vasculature, 
impaired tumor growth, reduced metastases and improved survival. Taken as a 
whole, this work demonstrates that directly inhibiting CCR5 expressing vasculature 
constitutes a novel strategy for inhibiting angiogenesis and blocking metastatic 
progression in breast cancer.
INTRODUCTION
For solid tumors to grow and spread they produce 
pro-angiogenic growth factors, such as vascular endothelial 
growth factor (VEGF) that promote the activation of 
surrounding host endothelial cells, as well as the recruitment 
of bone marrow (BM) derived endothelial progenitor 
cells (EPCs) [1-6]. Blocking VEGF/VEGF receptor 2 
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(VEGFR2) signaling using anti-angiogenic agents such as 
bevacizumab leads to defects in EPC biology, as well as 
impaired tumor growth and spread [7, 8]. However, many 
tumor types including those of the breast are non-responsive 
to treatment, while others develop resistance. Thus, the 
clinical benefit of bevacizumab remains controversial [9]. 
A key driver of resistance to anti-angiogenesis therapy has 
been identified as the increased expression of pro-angiogenic 
tumor-derived growth factors [10].
The chemokine (C-C motif) ligand 5 (CCL5; aka 
RANTES) is an 8kDa peptide that is up-regulated in breast 
tumors, and has been associated with metastatic spread 
[11-13]. CCL5 produced by mesenchymal stem cells 
(MSCs) acts to induce malignancy-associated changes 
in breast cancer cells to promote spread through binding 
with its cognate receptor, CCR5 [14]. In addition, recent 
work has also suggested a role for CCL5/CCR5 signaling 
in neovascularization, including as a key factor in EPC 
mediated angiogenesis [15]. For instance, wound healing has 
been shown to be CCR5 dependent [16, 17], while CCR5 
antagonist administration results in reduced metastasis [18], 
and primary breast tumors that are less vascular (paler) 
than controls [19]. Although work from our laboratory and 
others has shown that CCR5 is expressed by EPCs [3] the 
mechanism of CCL5/CCR5 signaling in EPC mediated 
breast tumor neovascularization remains unclear.
Herein, using suppression of CCL5 in two 
immune competent murine breast cancer models, we 
demonstrate a paracrine role for cancer cell CCL5 in 
tumor neovascularization and growth. We further confirm 
expression of CCL5 receptors (CCR1 & CCR5) by EPCs, 
as well as significant tumor growth and angiogenesis defects 
in CCR5 null mice. However, ablation of CCR5 in the BM 
does not result in tumor vascular defects, while CCR5 null 
mice transplanted with wild type (WT) BM show tumor 
angiogenesis and growth defects, which phenocopy those 
observed in CCR5 null animals. This suggests that the 
defects observed in CCR5 null mice are not due to reduced 
numbers or functionality of EPCs. Instead, vascular defects in 
CCR5 null animals may be the result of defects in paracrine 
signaling between cancer cell CCL5 and vasculature resident 
in the tumor microenvironment. In support of this finding, 
we have identified a subpopulation of CCR5 expressing 
endothelial cells in the breast tumor microenvironment, and 
describe a clinical correlation between vascular expression 
of CCR5 and invasive tumor grade. We further demonstrate 
that suppression of endothelial CCL5/CCR5 signaling leads 
to defects in mTOR/AKT pathway activation [20], as well 
as vascular and tumor growth defects in vitro and in vivo.
RESULTS
Cancer cell produced CCL5 is required for 
tumor angiogenesis and growth
EO771 and 4T1 breast cancer cells were stably 
transduced with lentiviral vector (LVs) encoding 
CCL5 short hairpin RNA (generated with either seed 
sequence 2 or 3) and orthotopically implanted into mice 
(Supplementary Figure S1A-E and Supplementary Table 
S1A-S1G). Suppression of cancer cell CCL5 lead to 
significantly impaired tumor growth in both syngeneic 
mouse models (P < 0.001) (Figure 1A, Supplementary 
Figure S2A, S2B, and Supplementary Table S2A-S2C). 
When the tumors were examined, vascular defects 
were observed in size-matched tumors (Day 14). Such 
defects included a reduced number of endothelial 
cells (EO771: P = 0.0285 and 4T1: P < 0.0001), and a 
reduction in tumor localized EPCs (P = 0.0239) (Figure 
1B, 1C, Supplementary Figure S2C and Supplementary 
Table S2D). Also evident, was a significant reduction 
in circulating EPCs (CEPs) (P = 0.033) (Figure 1D 
and Supplementary Table S2E), as well as a reduction 
in the number of BM resident EPCs (Figure 1D and 
Supplementary Table S2F). Thus, in vivo suppression of 
cancer cell CCL5 led to diminished tumor growth and 
vascular effects. However, as autocrine suppression of 
CCL5 did not result in significant proliferation defects in 
vitro, any effects on tumor growth and vasculature from 
suppression of cancer cell CCL5 are likely explained 
by paracrine signaling to the host microenvironment 
(Supplementary Figure S1F-S1G).
Ablation of host CCR5 impairs tumor 
angiogenesis and growth
To assess the importance of paracrine signaling 
by cancer cell produced CCL5, EO771 cells were 
orthotopically injected into mice that were homozygous 
null for CCR1 (CCR1-/-), and/or CCR5 (CCR5-/-). Cancer 
cells grown orthotopically in the mammary gland of CCR5 
null mice, but not CCR1 null mice, showed dramatically 
reduced tumor growth, compared to control wild-type 
(WT) animals (P < 0.0001) (Figure 2A and Supplementary 
Table S3A). Moreover, histological examination of 
size matched tumors that were harvested just prior 
to exponential growth (Day 14), revealed significant 
angiogenic defects in CCR5 null mice, including reduced 
vessel branching (P < 0.0001), decreased vascular density 
(P = 0.0273), and reduced tumor endothelial cell numbers 
(P = 0.0002) (Figure 2B and Supplementary Tables S3B-
S3D). In agreement with previously published studies 
[2, 4], the number of EPCs in the BM of CCR5 null 
transgenic mice expanded in response to tumor challenge 
(P = 0.0478) (Figure 2C and Supplementary Table S3E).
Next, to determine whether ablation of CCR5 
inhibits the propensity of breast cancer cells to establish 
lesions in the lungs, mCherry labelled [21] EO771 
cells were injected into the tail-vein of CCR5-/- mice. 
CCR5-/- mice survived longer than control animals 
(P = 0.022) (Figure 2D, Supplementary Figure S3A, 
and Supplementary Table S4A), and metastases 
were less vascular, than those identified in control 
animals (P = 0.0037) (Supplementary Figure S3A-
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S3C and Supplementary Table S4B). Taken together 
the tumor growth and vascularization defects observed 
following ablation cancer cell of CCL5, and in CCR5 
null mice, strongly support a role for tumor CCL5/ 
host CCR5 paracrine signaling in tumor growth and 
neovascularization.
CCR5 is not required for BM-mediated tumor 
growth and angiogenesis
Work by ourselves and others has shown that BM 
EPCs express both mRNA [3] and protein for CCR1 and 
CCR5 (Supplementary Figure S4A-S4D). Therefore, to 
determine the relative contribution of BM CCL5 receptor 
expression to tumor growth and neovascularization, BM 
from CCR1 or CCR5 null mice was transplanted into 
WT animals. For comparison, BM from WT mice was 
transplanted into CCR5 null animals (Supplementary 
Figure S5A). Following reconstitution, BM transplanted 
(BMT) animals were orthotopically implanted with 
EO771 breast cancer cells. Notably, tumor growth in 
WT mice transplanted with CCR1 null (WT:CCR1-/-), or 
CCR5 null BM (WT:CCR5-/-) did not significantly differ 
from tumors growing in WT mice reconstituted with WT 
BM (WT:WT). In contrast, EO771 tumors implanted in 
CCR5 null mice transplanted with WT BM (CCR5-/-:WT) 
showed significantly reduced growth (Figure 3A and 
Supplementary Table S5A), and a significant reduction 
Figure 1: Cancer cell produced CCL5 is required for breast tumor growth and vascularization. A. Growth curve of WT 
mice showing a significant reduction in the growth of EO771:EFlong-eGFP-CCL5Ω (seed sequence 2), compared with EO771:EFlong-eGFP-
NSΩ tumors. Data was analyzed by MANOVA (α = 0.05, ‘**’P < 0.01, n = 10 per group). Tumor morphology as inset. Scale Bar, 10 mm. 
B. FACS analysis showing a significant reduction of tumor CD31+ CD11b- endothelial cells (ECs) and tumor associated c-kit+ VEGFR2+ 
CD11b- EPCs in EO771:CCL5Ω, compared with nonspecific control (EO771:NSΩ) tumors. Data is represented as mean number cells ± 
S.E.M. per 102, or 103 total cells (n = 5 per group). C. Immunostaining of vasculature (CD31+) from EO771:CCL5Ω and control tumors. 
Scale bar, 200 μm. D. FACS analysis showing a significant reduction in circulating endothelial progenitors (CEPs) (Left) and no significant 
difference in BM EPCs isolated from mice transplanted with EO771:CCL5Ω tumors (Right). Data is represented as either mean number per 
1 × 103 PB mononuclear cells (PBMNCs) or c-kit cells ± S.E.M. (n = 5 per group). For B & D, data was analyzed by Unpaired t test (‘*’P 
< 0.05, ‘**’P < 0.01; α = 0.05).
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in vessel branching (P < 0.0001), as well as a reduction 
(~50 %) in numbers of CCR5+ tumor-recruited endothelial 
cells (P < 0.0001) (Figure 3B, 3C, and Supplementary 
Table S5B, S5C).
The BM of BMT mice was then examined to 
determine whether defects in BM EPCs might explain 
the impaired growth and vascular defects observed. 
However, analysis of BM following reconstitution 
showed no significant difference in levels of EPCs, 
myeloid progenitors (MPs), or neutrophil progenitors 
(NPs) (Supplementary Figure S5B and Table S5D-S5G). 
Notably, no reduction in levels of CCR5+ BM EPCs was 
observed in CCR5-/-:WT BMT mice (Supplementary 
Figure S5C); while BM-EPCs and CEPs in WT:CCR5-/- 
BMT animals responded normally to tumor challenge 
(Figure 3D). Furthermore, there was no observable 
reduction in the number of tumor recruited EPCs in 
animals with CCR5 null BM (Supplementary Figure 
S5D). Therefore, while absence of CCR5 in the non-
BM compartment of the tumor-stroma lead to vascular 
defects, and a reduction in the number of tumor 
recruited CCR5+ endothelial cells, in the absence of 
BM CCR5 EPCs still proliferated and migrated to the 
blood and tumor-stroma. Taken together, these findings 
indicate that the vascular defects observed in CCR5 
null mice are not the result of impaired EPCs biology, 
Figure 2: Breast tumor growth and angiogenesis in CCR5 null mice. A. Left, growth curve of EO771 breast cancer cells 
showing a significant decrease in tumor growth when grown in CCR5-/- null mice, compared with CCR1 null (CCR1-/-) or wild-type (WT) 
animals. Data is represented as mean volume ± S.E.M., and was analyzed by MANOVA (‘**’P < 0.01; α = 0.05, n = 10 per group). Right, 
Representative tumors (Day 14 & Day 28). Scale bar, 15 mm. B. Upper Left, shown, a significant decrease in tumor vascular branching 
in CCR5-/- null mice, compared with control (WT) mice. Data is represented as mean number of branch points/field ± S.E.M. (n = 20 
per group). Upper Middle, shown, a significant decrease in tumor vascular density in CCR5-/- mice. Data is represented as mean CD31+ 
vasculature area/field, corrected for tumor area ± S.E.M. (n = 20 per group). Upper Right, FACS analysis of tumors showing a significant 
reduction in the number of CD31+ CD11b-endothelial cells (ECs) in CCR5-/- mice, compared with WT mice. Data is represented as mean 
number of endothelial cells (ECs) per 103 total cells ± S.E.M. Lower, CD31 immunostaining of representative tumors, showing significantly 
less vascular branching and density in CCR5-/- mice compared with WT mice. Scale bar, 200μm. For B & C, data was analyzed by Unpaired 
t test (‘*’P < 0.05, ‘**’P < 0.01; α = 0.05). C. FACS analysis of bone marrow (BM) at day 14 from tumor challenged mice, showing 
expansion of VEGFR2+ c-kit+ CD11b- EPCs in both WT (P = 0.0125), and CCR5-/- animals (P = 0.0478). Data is represented as mean 
number of cells per 103 BM mononuclear cells (BMMNCs) ± S.E.M. (n = 5 per group). D. Survival data of CCR5-/- and WT mice after tail 
vein injection of 1 × 105 EO771 cells (n = 7) showing significantly increased survival in CCR5-/-mice. Data was analyzed by Kaplan-Meier 
estimator (‘*’P < 0.05, α = 0.05).
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Figure 3: Tumor growth and angiogenesis in CCR5 null mice transplanted with wild-type (WT) bone marrow (BM). 
A. Growth curves of EO771 tumor cells grown in WT mice transplanted with WT, CCR1 null (CCR1-/-) and CCR5 null (CCR5-/-) BM 
(recipient:donor), as well as CCR5-/- mice transplanted with wild-type (WT) BM (CCR5-/- :WT), showing a significant decrease in tumor 
growth in CCR5-/-:WT mice. Data is represented as mean tumor volume ± S.E.M. (n = 6), and analyzed by MANOVA (‘**’P < 0.01; α = 
0.05). B. Shown a significant decrease in vascular branching in CCR5-/-:WT mice, compared with WT:WT animals. Data is represented 
as number of branch points/field ± S.E.M. (n = 20 per group). C. The number of CCR5+ CD31+ CD11b- tumor endothelial cells (ECs) is 
significantly reduced in CCR5-/- transplanted with WT BM, compared with CCR1-/- transplanted with WT BM and control BMT mice. Data 
is represented as mean number of ECs per 103 total CD31+ CD11b- tumor ECs. D. FACS analysis of BM EPCs and peripheral blood (PB) 
CEPs from WT:CCR5-/- animals, showing expansion of VEGFR2+ c-kit+ CD11b- EPCs (Left), and CEPs (Right), after tumor challenge. 
Data is represented as mean number of EPCs (or CEPs) per 102 BMMNCs/PBMNCs ± S.E.M. For B-D, data was analyzed by Unpaired t 
test (‘*’P < 0.05, ‘**’P < 0.01; α = 0.05).
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but instead, may be explained by defects in signaling 
to CCR5 expressing endothelial cells in the tumor 
microenvironment.
Endothelial CCR5 expression is increased 
in response to tumor conditioned media and 
correlates with invasiveness in breast cancer
Mouse and human endothelial cells were treated 
with media pre-conditioned by exposure to mouse and 
human breast cancer cell lines. CCR5 mRNA was up-
regulated, by at least two-fold (P < 0.05), in murine 
endothelial cells treated with pre-conditioned media 
from murine breast cancer cell lines (EO771, 4T1), 
and the highly angiogenic Lewis lung carcinoma line 
(LLCs). CCR5 mRNA was also up-regulated in human 
endothelial cells exposed to media conditioned by 
MDA-MB-231 human breast cancer cells (Figure 4A 
and Supplementary Table S6). 
When tumor vasculature was examined by 
immunofluorescence (IF) in situ, CCR5+ endothelial 
cells were identified in EO771, 4T1 and LLC tumors, 
with 2-20 % of tumor endothelial cells expressing CCR5 
(Figure 4B and Supplementary Figure S6A, S6B). To 
account for vascular mimicry mCherry FACS exclusion 
was used (Supplementary Figure S7A, S7B) [22].
We next examined CCR5 vasculature in Triple 
Negative (TNBC), Human Epidermal Growth Factor 
Receptor 2 (HER2)+ and Estrogen Receptor (ER)+ breast 
cancers; as well as ductal carcinoma in situ (DCIS) [23]. 
In agreement with results of mouse studies, CCR5 was 
found to be expressed in a sub-population of human 
breast tumor vessels (Figure 4C, 4D). Interestingly, the 
number of CCR5+ endothelial cells, as a proportion of 
total vasculature, was higher in malignant tumors than in 
Figure 4: CCR5 expressing vasculature and pathology. A. Upper, High resolution (63×) fluorescent microscopy showing CCR5 
expression in murine (MHEVC) and human (HUVEC) endothelial cells (ECs) in vitro. Scale bar, 20 μm. Lower, Q-PCR showing significant 
induction of CCR5 mRNA in murine and human ECs, in response to murine (EO771, 4T1 & LLC) and human (MDA-MB-231) tumor 
conditioned medium, respectively. Data is represented as mean Log2(Fold) ± S.E.M. (n = 5 per group). B. High resolution (63×) fluorescent 
microscopy showing that CD31+ endothelial cells (ECs) express CCR5+ in EO771 tumors in situ (arrows). Lower Right, Results of FACS 
analysis showing the percentage of CD31+ CD11b- ECs that are CCR5+ in EO771 tumors. Data is represented as a mean percentage of the 
total number of tumor ECs ± S.E.M. C. High resolution (40×) fluorescent microscopy Z-stack showing that CD31+ vasculature in human 
HER2+ breast cancers express CCR5. Scale bar, 10 μm. D. Fluorescent microscopy showing estrogen receptor (ER)+ (Upper) and triple 
negative (TNBC) (Lower) tumors, with CCR5 positive and negative vessels (red boxes) and ECs (yellow boxes). Scale bar, 50μm. E. 
Scoring analysis of CCR5 expression in CD31+ vasculature from TNBC, HER2+, ER+ and DCIS human breast cancers. Dot plot showing a 
significantly higher number of CCR5+ CD31+ tumor blood vessels in TNBC, HER2+ and ER+ tumors compared with DCIS. At least 10 fields 
were analyzed per section. For A, B & E, data was analyzed by Unpaired t test (‘*’P < 0.05, ‘**’P < 0.01; α = 0.05).
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DCIS lesions: TNBC, P = 0.0017; HER2+, P = 0.0138; 
ER+, P < 0.0001 (Figure 4E and Supplementary Table 
S6B, S6C). Collectively, these findings indicate that 
vascular scoring with CCR5 in human tumors can be used 
as an indicator of malignancy, and that CCR5+ vasculature 
represents a clinically relevant sub-population in the tumor 
microenvironment.
Suppression of CCL5/CCR5 leads to angiogenic 
defects in vitro and in vivo
Next, murine and human endothelial cells treated 
with either siRNA inhibiting CCR5, or the CCR5 
antagonist maraviroc, underwent endothelial tube 
formation assays in vitro (Supplementary Figure S8A-
S8C and Supplementary Table S7A-S7C). Suppression 
of CCR5 led to significantly reduced tube length in 
endothelial cells (~10-30 % reduction). Maraviroc was 
then administered orally to mice implanted with mCherry 
labelled 4T1 tumor cells. Mice treated with maraviroc 
displayed delayed tumor growth for the period of treatment 
(Days 7-17; P < 0.05) (Figure 5A and Supplementary Table 
S8A). When maraviroc treatment ceased, tumor growth 
resumed and caught up with controls, although tumors 
were paler at harvest. Maraviroc-treated mice also showed 
no change in total weight or spleen weight compared 
with untreated animals (Supplementary Tables 8B,C). 
Histological examination conducted at end point (Day 28) 
revealed that treated tumors had a smaller growing margin 
(hematoxylin+) (Supplementary Figure S9A) and were less 
vascular (CD31+) than controls (Supplementary Figure 
S9B). In a parallel experiment, tumors were resected after 
treatment and mice allowed to develop metastases. In 
this case, tumor resected animals showed fewer numbers 
of circulating tumor cells (CTCs: P = 0.0461) [24] and 
fewer lung metastases (Supplementary Figure S9C, S9D 
and Supplementary Table S8D). This result suggested 
that angiogenesis is activated at least in part by signaling 
through CCR5.
To examine this pathway further we treated mouse 
and human endothelial cells, with CCL5, or tumor 
conditioned media, and demonstrated that migration is 
significantly impaired following siRNA suppression of 
CCR5 (Figure 5B and Supplementary Table S9A, S9B). 
We have also shown that while CCL5 treatment results 
in the phosphorylation/activation of downstream effectors 
of CCR5 activation; including members of the AKT/
mTOR pathway (4EPBP1 & mTOR) [20]; suppression of 
CCR5 activation by maraviroc, or CCR5 siRNA treatment, 
lead to specific activation (phosphorylation) defects in 
members of this pathway (GSK-3α/GSK-3β) in murine 
endothelial cells (Figure 5C, Supplementary Figure S10A, 
S10B and Supplementary Table S10A, S10B).
Taken as a whole this work strongly suggests that 
CCL5 acts through CCR5 to promote angiogenesis, and 
that tumor neovascularization mediated by CCL5/CCR5 
is not BM dependent. Furthermore, inhibition of mTOR/
AKT signaling in endothelial cells may, at least in part, 
explain the anti-angiogenic effects observed following 
suppression of CCL5/CCR5 in vitro and in vivo.
DISCUSSION
In previous work, CCL5/CCR5 antagonism has 
been shown to inhibit breast tumor metastasis [18], 
leading to tumors that are pale and necrotic [19]. 
This has implied that signaling through CCL5/CCR5 
is needed for tumor vascularisation in breast cancer. 
However, previous work has been conducted in immune 
suppressed animals [18], making the contribution of 
cancer cell derived CCL5 to tumor angiogenesis in 
breast cancer difficult to assess. Moreover, Weinberg 
and others have proposed that CCL5 produced by 
mesenchymal stem cells (MSCs), directly acts on breast 
cancer cells to promote proliferation and spread [14]. 
Therefore, to determine the specific contribution of 
cancer cell derived CCL5 to angiogenesis we stably 
suppressed CCL5 in immune competent breast tumor 
models. In this work, we demonstrate that distinct tumor 
angiogenesis defects associated with suppression of 
cancer cell CCL5 are associated with a reduced number 
of tumor EPCs, and a reduction in the number of CEPs.
Next, to investigate the paracrine mechanism that 
cancer cell CCL5 operates to promote angiogenesis, we 
orthotopically implanted breast cancer cells into mice, 
which were homozygous null for either CCR1 or CCR5. 
At the start of the angiogenic switch (Day 14) tumors 
were significantly less vascular in CCR5 null animals 
than size matched tumors grown in CCR1 null or control 
animals. Further, the expected mobilization of EPCs into 
the peripheral blood in response to tumor challenge [2] 
was also impaired in CCR5 null animals. Delayed tumor 
growth and metastasis in CCR null mice has previously 
been reported by van Deventer and others [25, 26]. In 
our hands, tail vein injection of breast cancer cells also 
resulted in higher survival rates in CCR5 null animals. 
Notably, lung established in CCR5 null animals tail vein 
injected with breast cancer cells, were smaller and less 
vascular than those in WT animals.
As EPCs express both CCR1 and CCR5, it has been 
suggested that homing of EPCs to maturing vasculature is 
chemokine dependent [3, 15, 27]. Thus loss of CCR5 in 
EPCs may, at least in part, explain the tumor phenotype 
we observed in CCR5 null animals [17, 18]. Unexpectedly, 
we found that tumor growth and angiogenesis was not 
inhibited in wild-type mice transplanted with CCR5 null 
BM. Conversely, transplantation of wild-type BM into 
CCR5-/- mice was not sufficient to rescue the reduced 
tumor growth and vascularization seen in CCR5 null 
mice, indicating that recruitment of CCR5+ BM-derived 
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cell populations does not significantly contribute to the 
pro-angiogenic effects of CCL5/CCR5 signaling in breast 
tumors. This result is consistent with reports showing 
that transfer of CCR5+ BM cells in CCR5 null animals 
does not rescue tumor growth defects in melanoma [25, 
26]. Additionally, as the number of BM EPCs was not 
significantly reduced in WT mice reconstituted with 
CCR5 null BM, the tumor growth and vascular phenotype 
associated with CCR5 ablation is likely due to a defect in 
the non-BM compartment of the tumor-microenvironment. 
Notably, while it has been shown that CCR5 plays a role in 
EPC tumor biology, this has only been demonstrated in the 
Figure 5: Pharmacologic inhibition of CCL5/CCR5 in a syngeneic model of breast cancer. A. Left, delayed tumor growth, 
following maraviroc administration, compared with controls. Treatment commenced on day seven, and was followed by twice daily oral 
administration (gavage) of 10 mg/kg (3 % DMSO) maraviroc. Controls received vehicle only. Right, Tumors resected from maraviroc-
treated animals (Day 13) were also paler. Scale bar, 10 mm. B. Left, Transwell assays showing significant number of mouse (MHEVS) and 
human (HUVEC) endothelial cells (ECs) migrated towards CCL5, compared to BSA control. Also shown (Right), a significant decrease in 
migration of human ECs in response to conditioned media from MDA-MB-231 breast cancer cells following siRNA suppression of CCR5, 
compared with scrambled siRNA control. Data is represented as mean number of migrated cells ± S.E.M. C. Left, Heat map of Pathscan 
AKT pathway analysis showing fold change in phosphorylation status of several members of the pathway in murine ECs, following 
treatment with CCL5 or suppression of CCR5 with maraviroc. Fold is determined by mean difference in average pixel density, between 
treated and control spots, following normalization. Right, Change in phosphorylation of GSK-3α (Ser21) and GSK-3β (Ser9) following 
treatment with CCL5, CCR5 siRNA or maraviroc, was confirmed by western blot analysis, and determined following normalisation against 
total GSK-3 protein. Tubulin was used as a loading reference. Data represented as mean % change in phosphorylation ± S.E.M. For B & C, 
data was analyzed by Unpaired t test (‘*’P < 0.05).
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later stages of tumor development, and after rapid growth 
and angiogenesis associated with the angiogenic switch 
[15]. Furthermore, a proportion of tumor associated EPCs 
may not be of BM origin [2, 28]. For instance, two distinct 
adipose-derived EPC populations based on expression of 
c-c chemokine receptor-like 2 (CCRL2) have recently 
been identified [29]; although whether they play a role 
in the phenotype observed in CCR5 null animals remains 
unknown.
We have also shown that CCR5+ endothelial 
cells represent a distinct and clinically significant 
population in the breast tumor microenvironment, with 
a significant correlation between endothelial CCR5 
expression and invasiveness. In vitro, endothelial cells 
treated with CCL5 also showed increased migration and 
activation of specific members of the AKT pathway, 
such as GSK3a/β [31]; whereas treatment with CCR5 
antagonist or siRNA targeting CCR5 resulted in reduced 
migration and suppression of downstream effectors. 
Finally, we have shown that maraviroc treatment in 
an immune-competent mouse model of breast cancer, 
results in impaired metastasis and tumor growth. 
Taken as a whole, this work does not discount a role 
for other cell types in the indirect regulation of vascular 
biology. Instead findings support a mechanism by which 
cancer cell-derived CCL5 may directly recruit tumor 
vasculature from existing vasculature. In addition, while 
impaired vessel co-option [30] may offer an explanation 
for the defects observed following CCR5 deletion/
suppression, in our hands inhibition of CCL5/CCR5 in 
endothelial cells resulted in specific mobilization defects 
in vitro. This finding supports supports the proposition 
that it is impaired recruitment of pre-existing ECs/
vessels (angiogenesis), which best explains the vascular 
and tumor growth defects observed following CCR5 
ablation or suppression in vivo.
In conclusion, specific therapies inhibiting CCL5/
CCR5 may not only prevent malignant progression, but 
also significantly delay tumor growth by inhibiting the 
angiogenic switch in primary tumors and disseminated 
micrometastases. Given the unwanted side effects 
associated with generalised anti-angiogenesis therapies, 
directly inhibiting cancer cell CCL5 signaling to 
endothelial cells may constitute a novel strategy for 
blocking angiogenesis, tumor growth and spread in breast 
cancer.
MATERIALS AND METHODS
Cell culture and preparation of retroviruses
MDA-MB-231 cells were obtained from ATCC 
(Manassas, VA). E0771 and 4T1 cells were provided by 
Prof Robin Anderson (Olivia Newton John Cancer Research 
Institute, Australia). MDA-MB-231, 4T1 and EO771 cells 
were maintained in DMEM with 10% Fetal Calf Serum 
(FCS) (Invitrogen, Carlsbad, CA). EO771 and 4T1 cell 
lines expressing mCherry [21] were created through the 
stable transduction of a retroviral construct containing 
the mCherry gene [32]. EO771 and 4T1 cell lines with 
CCL5 KD were created through stable transduction of a 
retroviral construct containing shRNAs designed to inhibit 
CCL5 [4]. Four different seed sequences were created 
using RNAi Codex (codex.cshl.edu) [33]: (i) CCL5Ω(1): 
5’-GAGAAGAAGTGGGTTCAAGAA-3’; (ii) CCL5Ω(2): 
5’-CGACCAAGAAATCAGCATTTCATT-3’; (iii) CCL 
5Ω(3): 5’-GGTTCAAGAATACATCAACTA-3’; and (iv) 
CCL5Ω(4): 5’-CGTGCCCACGTCAAGGAGTAT-3’. LLC/
D122’s were provided by L. Eisenbach (Wiesman Institute 
of Science, Rehovot, Israel), and maintained in RPMI with 
10 % FCS. HUVECs were obtained from ATCC, grown on 
0.1 % gelatin (Sigma-Aldrich), and maintained in EGM-
2MV BulletKit™ media (Lonza, Valais, Switzerland). 
MHEVCs were provided by J. Cook-Mills (University of 
Cincinnati, Cincinnati, OH) [34], and maintained in RPMI 
with 10 % FCS. Cell authentication was conducted by 
short tandem repeat profiling, cell morphology monitoring, 
karyotyping, and the ATCC cytochrome c oxidase.
Lentivirus (LV) particles pseudotyped with the 
vesicular stomatitis G protein (VSVG), were generated 
by calcium phosphate transfection of three packaging 
constructs, pSPAX (REV/RRE) and pVSVG into human 
embryonic kidney (HEK) 293T cells [32]. Viral titer was 
determined by FACS analysis of LV-infected 293T cells. 
LV transductions of cell lines were performed in the 
presence of Polybrene® (Sigma-Aldrich). Cells transduced 
with PGK-mCherry were assessed for their similarity in 
growth and pathology to the parental line. 293T cells were 
obtained from ATCC and grown in DMEM, with 10 % 
FCS, and Sodium Pyruvate (1 mM).
Tumor growth and bone marrow transplantation 
(BMT) studies
Female C57BL/6 mice and BALB/c mice and were 
obtained from the Animal Resources Centre (Canning 
Vale, Western Australia). All procedures involving mice 
were conducted in accordance with protocols reviewed 
and approved by institutional animal care and ethics 
committees. Mice homozygous null for CCR1 (B6.129S4-
Ccr1tm1Gao) and CCR5 (B6.129P2-Ccr5tm1Kuz/J) were 
sourced from The Jackson Laboratory, Bar Harbor, MN) 
[35, 36]. BMT was conducted according to previously 
published protocols [4]. In this study, 1 × 107 total Wild-
type (WT), CCR1-/-, or CCR5-/- total BM cells were 
injected into the tail veins of lethally irradiated (1100 
rads) C57BL/6 mice, CCR1 null (-/-), and or CCR5 null 
(-/-) recipients. Mice were used in tumor growth studies 
following reconstitution (8 weeks). Unless otherwise 
stated, mice were injected with 5 × 104 breast cancer cells, 
orthotopically in the mammary fat pad of either C57BL/6 
(EO771) or BALB/c (4T1) mice. Tumor size was 
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measured using standard methods, and volume calculated 
using the following equation: (short axis)2 × (long axis) × 
0.5236 [2, 4].
Immunohistochemistry
Mouse tissues were fixed (4% PFA), and 
cryopreserved in optimal cutting temperature (O.C.T.) 
medium (Tissue-Tek, Elkhart, IN), and prepared as 10-
30 μm thick sections. Mononuclear cells from the blood 
and BM were isolated by gradient centrifugation using 
Histopaque-1077 (Sigma-Aldrich, Milwaukee, WI) and 
centrifuged onto Superfrost Plus Slides (Menzel-Glaser, 
Braunschweig, Germany). Unless otherwise stated, all 
tissues were stained with Alexa Fluor® (Invitrogen), or 
Phycoerythrin (PE) conjugated primary antibodies, as 
well as with DAPI. Rat or hamster anti-mouse primary 
antibodies: CD31/PECAM-1 (clone MEC13.3), VE-
Cadherin/CD144 (clone 11D4.1), CD11b (clone M1/70), 
VEGFR2/Flk1 (clone avas12α1), CCR5/CD195 (clone 
C34-3448), c-kit/CD117 (clone 2B8), Ly-6G and Ly-
6C/Gr-1 (clone RB6-8C5), CD4 (clone RM4-5) and 
CD61/Integrinβ3 (clone 2C9.G2) were obtained from 
BD Biosciences. We also used CCR1/CD191 (clone 
C-20), reactive against mouse and human, were Santa 
Cruz Biotechnology (Santa Cruz, CA). Rat Anti-Mouse 
Ki-67 eFluor® 570 (SolA15) was purchased from 
eBioscience [4].
Formalin-fixed human breast cancer biopsies 
cryopreserved in O.C.T were provided by the Breast 
Cancer Tissue Bank (www.abctb.org.au). Biopsies 
were collected by Westmead Hospital, NSW, Australia 
under protocols reviewed and approved by institutional 
human ethics committees. In this study, biopsies were 
prepared as 10 μm thick transverse sections, prior to 
immunofluorescence analysis. For staining of human 
tissues we used mouse monoclonal anti-CCR5 (D-6) 
from Santa Cruz Biotechnology, and mouse anti-human 
CD31 (clone WM59) fromBD Biosciences. Images were 
obtained using the Zeiss M2 fluorescent microscope 
(Software Axiovision Version 4.8, Carl Zeiss, Aalen, 
Germany), as described [2-4].
Flow cytometry
For FACS, cell suspensions were filtered (70 μm), 
pre-blocked with Fc block CD16/CD32 (BD Biosciences), 
and incubated with Alexa-dye, phycoerythrin (PE), or 
Allophycocyanin (APC) conjugated primary monoclonal 
antibodies. A rat monoclonal anti-mouse TER-119 
(clone TER-119) antibody (BD Biosciences) was used 
as an erythroid marker [2-4]. Isotype, fluorescent minus 
one (FMO), and unstained controls were all used for 
determining appropriate gates, voltages, and compensation 
[37], using the BD Fortessa LSRII flow cytometer with 
FACS Diva software (BD Biosciences).
For FACS analysis we have defined EPCs as 
CD11b- VEGFR2+ VE-cadherin+ c-kit+ and Ter119-, 
myeloid progenitors as CD11b+ c-kit+ Ter-119-, neutrophil 
progenitors as GR1+ CD11b+ c-kit+, and endothelial cells 
as CD11b- CD31+. Because of relative marker levels in 
different tissues, tumor EPCs are specifically isolated as 
VE-cadherin+ CD11b- c-kit+ Ter-119- cells, while in the 
blood and BM VEGFR2+ c-kit+ CD11b- Ter-119- cells [2, 
4, 27] (Supplementary Figure S11). Analysis of tumor, 
BM and blood EPC populations was conducted prior to 
the angiogenic switch (~Day 14 for EO771s) from mice 
sacrificed at this time.
Tubule formation, wound healing and migration 
assays
For tube formation endothelial cells were grown 
on Matrigel™ (BD Biosciences, following standard 
methods [27]. Tube number and length were analyzed 
from randomly selected fields. For wound healing a 
scratch (wound) was made across a cell monolayer using 
a sterile tip. Image analysis was conducted using ImageJ 
software. Relative clearance rate was determined using the 
equation: (distance=0h – distance=24h)/ distance=0h × 100 % 
[27]. For migration assays, we used a transwell 8 µm 
polycarbonate membrane assay (Corning, Tewksbury, 
MA), with either conditioned media, or recombinant 
purified CCL5/RANTES (10 nM) (PreproTech, Rocky 
Hill, NJ) as chemoattractant. After four hours membranes 
were imaged using the IX71 fluorescent microscope and 
counted using CellSens Dimensions software (Olympus, 
Tokyo Japan).
Endothelial cells were transfected with siRNAs 
(0.04 pmol/μl) using siPORT NeoFX Transfection Agent 
(Ambion, Carlsbad, CA) [27], and/or treated with the 
small molecular inhibitor of CCR5, maraviroc (100 nM). 
Pooled siRNAs specifically designed to inhibit mouse or 
human CCR5 (siGENOME SMARTpool) and Cyanine 
3 (Cy3) labeled siGLO RISC-Free Control siRNA were 
obtained from Thermo Scientific (Waltham, MA).
Quantitative protein analysis
A CCL5 enzyme linked immunosorbent assay 
(ELISA) was used to quantitatively assess protein 
levels following CCL5 shRNAi transduction. ELISA 
followed the mouse CCL5/RANTES DuoSet protocol 
(R&D Systems, Minneapolis, MN). Microtitre plates 
were coated with CCL5-specific capture antibody 
overnight, washed three times and blocked for 1 hour 
with 1 % bovine serum albumin (BSA) in phosphate 
buffered saline (PBS). Detection antibody was goat 
anti-mouse CCL5 (R&D Systems). A standard curve 
was prepared using CCL5 protein by serial dilution 
with the colorimetric density of each well measured 
(450 nm). Duplicate assays were performed and results 
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presented as the mean protein concentration (pg/ml) 
either secreted, or cell bound.
The PathScan® Akt Signaling Antibody Array 
Kit was conducted with fresh lysate (Cell Signaling 
Technology, Danvers, MA). After treatment with 
LumiGLO®, the chemiluminescence readout was 
visualised using the ChemiDoc XRS+ Imaging System 
and quantified using the Image Lab Software, Version 
2.0.1 (Bio-Rad). Western blots were performed on 
maraviroc and CCL5 treated (10 nM) endothelial cell 
lysate using GSK-3 Antibody Sampler kit (1:1000, No: 
9369, Cell Signalling Technology, Danvers, MA) and 
mTOR substrates Antibody Sampler kit (1:1000, No:9862, 
Cell Signalling Technology, Danvers, MA). Anti-CCR5 
antibody (1:1000 dilution; M-20, Santa Cruz) and the 
house keeping gene α/β-Tubulin (1:1000, No:2148, Cell 
signaling), was also used. Primary antibody was detected 
with horseradish peroxidase (HRP)–anti-mouse IgG at 
1:2000 (No:7074, Cell Signalling). Blots were developed 
with WestPico Supersignal (Pierce Biosciences, Rockford, 
IL) and chemiluminescence recorded using either the 
ChemiDoc XRS system (Bio-Rad Hercules, CA), or 
Fujifilm LAS 4000 image analyser.
mRNA expression analysis
Q-PCR analysis using SYBR Green I was performed 
on the Rotor-Gene Q 2plex (Qiagen, Germantown, 
MD). Primers used for murine CCL5: forward: 5’- 
TACCATGAAGATCTCTGCAGCT and reverse:  
5’-CTGCTGGTGTAGAAATACTCCT-3’. Levels of 
mRNA were normalized to 18S RNA using primers: 
forward: 5’-CTTAGAGGGACAAGTGGCG-3’ & reverse: 
5’-ACGCTGAGCCAGTCAGTGTA-3’. Primers used for 
murine CCR5 (forward: 5’-CTGGACTCCCTACAACA 
TTG -3’ and reverse: 5’- ACACTGAGAGATAACTCCG 
G-3’); and human CCR5 (forward: 5’-CTGGGCTCCCTA 
CAACATTG-3’ and reverse: 5’-TGCAGGTGACAGAG 
ACTCTTG-3’).
Statistical & data analyses
Statistical analyses were performed using Prism™ 
version 3.0 (GraphPad, La Jolla, CA). One-way 
MANOVA (α = 0.05) was used to compare differences 
in tumor growth. For comparison of the different cell 
populations following FACS Unpaired t test analysis 
was used (α = 0.05). Quantitative differences are 
represented as Log2(Fold) values (or ΔΔCT), and 
significance was determined through comparison of the 
difference in the two of ΔCT values, using Unpaired 
t test (α = 0.05) [38]. For vascular scoring (vascular 
branch point & vascular density analysis) images 
were imported into ImageJ software (v1.44, National 
Institutes of Health, Bethesda, MD). The total vascular 
density was calculated as a percentage of total tumor 
area, and branch points were counted by tallying each 
bifurcation point. Unless otherwise stated Unpaired 
t test analysis was applied to vascular scoring data, 
as well as data collected following analysis of tube 
formation and wound healing (α = 0.05).
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